AI Article Synopsis

  • The study aimed to evaluate the safety and effectiveness of using stent grafts (SGs) to treat complications from persistent sciatic artery (PSA), analyzing data from various sources up to September 2023.
  • A total of 40 patients underwent endovascular treatment with SGs, showing a 100% technical success rate, with specific adverse events reported but no severe complications.
  • The midterm outcomes demonstrated high clinical success rates (100% at 1 year, 95.7% at 2 years) and acceptable patency rates, suggesting that endovascular therapy with SGs is a safe and effective first-line treatment for PSA complications.

Article Abstract

Purpose: To evaluate the safety and effectiveness of endovascular therapy with stent grafts (SGs) to treat complications associated with persistent sciatic artery (PSA) by conducting a systematic review.

Materials And Methods: The MEDLINE, Web of Science, Scopus, and Ichushi Web databases were searched to identify articles focusing on endovascular treatment with SGs for complications associated with PSA published from inception to September 15, 2023. The review included 31 case reports, 2 case series, and 7 conference proceedings. Forty patients (median age, 67 years [range, 22-88 years]; 25 women) with 41 limbs underwent endovascular treatment with 65 SGs for ischemia (n = 26), aneurysm (n = 13), and trauma (n = 2). Prior treatments were systemic anticoagulation (n = 7), thrombolysis (n = 5), thrombectomy (n = 3), and amputation (n = 1), whereas concurrent treatments were thrombolysis (n = 6) and thrombectomy (n = 2). The median number of SGs implanted was 2 (range, 1-4). Early outcomes were technical success and adverse events (AEs). Late outcomes were primary patency, secondary patency, freedom from reintervention, and clinical success.

Results: The technical success rate was 100%. Intervention-specific AEs were reported in 4 cases; however, there were no severe AEs. The clinical success rates at 1 and 2 years were 100% and 95.7%, respectively. The primary patency rates at 1 and 2 years were 81.5% and 67.6%, respectively, and the secondary patency rates at 1 and 2 years were 94.5% and 81.6%, respectively.

Conclusions: Endovascular treatment with SGs for complications associated with PSA is safe and effective with acceptable midterm patency and durability, and is supportable as the first-choice treatment.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jvir.2024.04.013DOI Listing

Publication Analysis

Top Keywords

endovascular treatment
16
complications associated
16
treatment sgs
12
rates years
12
n =
9
safety effectiveness
8
effectiveness endovascular
8
associated persistent
8
persistent sciatic
8
sciatic artery
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!